Trial Profile
Urate lowering drugs RandomIzed parallel-group Comparison study in the Chronic Kidney Disease patients with hypertension and hyperuricemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2020
Price :
$35
*
At a glance
- Drugs Benzbromarone (Primary) ; Febuxostat (Primary)
- Indications Hypertension; Hyperuricaemia; Renal failure
- Focus Therapeutic Use
- Acronyms URIC-CKD study
- 11 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 New trial record